Cancer — Buy

The following table highlights multi-billion dollar deals where established giants moved to buy specialized oncology companies: Target Biotech Value (Up to) Primary Cancer Focus Kelonia Therapeutics $7 Billion Blood Cancer (CAR-T) Abbott Exact Sciences $21 Billion Early Screening/Diagnostics Gilead Tubulis $5 Billion Ovarian & Lung Cancer (ADCs) Gilead Arcellx $7.8 Billion Multiple Myeloma Johnson & Johnson Halda Therapeutics $3.1 Billion Prostate Cancer Genmab Merus $8 Billion Head and Neck Cancer Novartis Synnovation (Pikavation) $3 Billion Breast Cancer Why These Deals are Happening

Financial analysts currently view certain cancer biotech stocks as strong opportunities: buy cancer

: Analysts maintain an Overweight rating , forecasting significant upside potential. If you're looking for more info, are you interested in: Specific types of cancer treatments (like CAR-T or ADCs)? Financial analysis of these stocks? Clinical trial details for these new acquisitions? Clinical trial details for these new acquisitions